

----- PRESS RELEASE -----

**Herpen, The Netherlands, June 6, 2024**

**Life Sciences company Orexa raises investments of € 340,000**

HERPEN, THE NETHERLANDS - Orexa B.V., a Dutch life sciences company that is developing a new medicine that increases food intake and supports health in patients, has completed a financing round of € 340,000. The investment will be used to start treating patients in Orexa's second Phase 2 clinical trial, which targets anorexia patients.

A total of 18 patients will be recruited in this double-blind, placebo-controlled phase 2 study. Treatment will occur for each hospitalized patient over a 4-week period, with an adaptive design. Patients will hereby receive individual variable doses according to predefined conditions. If the dosage is well tolerated, but no positive effects are yet seen, then the dosage can be increased to an optimal, maximally effective dose.

The study will take place in Italy, in a specialized clinic where severely ill anorexia patients are admitted and treated. Dosing of the first patient is anticipated in H2-'24.

In addition to this study in anorexia patients, Orexa already has its first Phase 2 clinical trial underway, in the prevention of postoperative ileus, and is in preparation for a third Phase 2 clinical trial, targeting the elderly people with malnutrition. In this way, the efficacy of Orexa's drug candidate ORE-001 can be investigated in different ways and in multiple indications.

**About Orexa:**

Orexa is developing a drug that increases food intake. The markets where increased food intake can lead to substantial health benefits are large. Orexa focuses primarily on the recovery of patients who have undergone surgery, anorexia patients and elderly people with malnutrition (sarcopenia). The company is founded in 2016 and is based in Herpen (North Brabant), The Netherlands. For more information, see [www.orexa.eu](http://www.orexa.eu).